We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: immunotherapy
MedXY News
EnglishTag

immunotherapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersclinical trialsartificial intelligenceHypertensionCardiologyoncologytype 1 diabetespublic healthMortalitydiabetesAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Optimizing Anti-GD2 Immunotherapy: Dinutuximab Beta Redefines Survival in Relapsed and High-Risk Neuroblastoma
newsDinutuximab Betaimmunotherapy

Optimizing Anti-GD2 Immunotherapy: Dinutuximab Beta Redefines Survival in Relapsed and High-Risk Neuroblastoma

By MedXY|Jan 20, 2026

Recent clinical trials establish dinutuximab beta as a cornerstone of neuroblastoma therapy, demonstrating significant survival benefits when combined with chemotherapy in relapsed cases, while clarifying that adding Interleukin-2 to standa

CYTOscore: A Triple-Cytokine Signature Predicts Survival and Response to Chemoradiotherapy Plus Anti-PD-1 in Esophageal Squamous Cell Carcinoma
GastroenterologybiomarkersCytokines

CYTOscore: A Triple-Cytokine Signature Predicts Survival and Response to Chemoradiotherapy Plus Anti-PD-1 in Esophageal Squamous Cell Carcinoma

By MedXY|Jan 19, 2026

A new serum cytokine-based risk score (CYTOscore) utilizing IL-8, CCL3, and CCL4 identifies ESCC patients likely to benefit from chemoradiotherapy combined with toripalimab, offering a non-invasive tool for personalized immunotherapy and pr

Neoadjuvant Lenvatinib Plus Pembrolizumab Achieves Robust Pathological Complete Response in Resectable Merkel Cell Carcinoma
Dermatologyimmunotherapylenvatinib

Neoadjuvant Lenvatinib Plus Pembrolizumab Achieves Robust Pathological Complete Response in Resectable Merkel Cell Carcinoma

By MedXY|Jan 19, 2026

A Phase II trial demonstrates that combining lenvatinib with pembrolizumab prior to surgery in Merkel cell carcinoma results in a 57.7% pathological complete response rate, suggesting a highly effective new strategy for managing resectable

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade
newsclinical trialsimmunotherapy

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

By MedXY|Jan 19, 2026

Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual che

Tafasitamab Plus R2 Regimen Sets a New Benchmark for Relapsed or Refractory Follicular Lymphoma: Insights from the inMIND Trial
Hematology-OncologyFollicular lymphomaimmunotherapy

Tafasitamab Plus R2 Regimen Sets a New Benchmark for Relapsed or Refractory Follicular Lymphoma: Insights from the inMIND Trial

By MedXY|Jan 14, 2026

The Phase 3 inMIND trial demonstrates that adding tafasitamab to lenalidomide and rituximab (R2) significantly improves progression-free survival in patients with relapsed or refractory follicular lymphoma, reducing the risk of disease prog

Serplulimab Plus Chemotherapy Sustains Survival Advantage in ES-SCLC: Insights from the ASTRUM-005 Trial and Novel Biomarker Profiles
newsbiomarkersimmunotherapy

Serplulimab Plus Chemotherapy Sustains Survival Advantage in ES-SCLC: Insights from the ASTRUM-005 Trial and Novel Biomarker Profiles

By MedXY|Jan 14, 2026

Updated ASTRUM-005 results confirm serplulimab’s significant survival benefit in extensive-stage small-cell lung cancer (15.8 vs. 11.1 months). Exploratory analyses identify a 15-protein signature and RB1/Notch mutations as potential

Breaking Resistance: SBRT Plus Cadonilimab Shows Promising Efficacy in Heavily Pretreated Refractory Solid Tumors
newsimmunotherapyoncology

Breaking Resistance: SBRT Plus Cadonilimab Shows Promising Efficacy in Heavily Pretreated Refractory Solid Tumors

By MedXY|Jan 14, 2026

A Phase 1b study demonstrates that combining SBRT with the bispecific antibody cadonilimab (PD-1/CTLA-4) is safe and effective for refractory solid tumors, yielding a 23.8% response rate and 7.2-month median PFS in patients who failed multi

Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial
Gastroenterologyadjuvant therapycamrelizumab

Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial

By MedXY|Jan 14, 2026

The Phase 2 ACC trial demonstrates that adjuvant camrelizumab combined with capecitabine achieves a median recurrence-free survival of 24.29 months for patients with resected intrahepatic cholangiocarcinoma, offering a promising and managea

High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial
Diabetes & EndocrinologyimmunotherapyPhòng ngừa sơ cấp

High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial

By MedXY|Jan 13, 2026

The POInT trial demonstrated that high-dose daily oral insulin does not prevent islet autoantibodies in infants at high genetic risk for type 1 diabetes. Despite its safety, the primary endpoint was not met, though genotype-specific interac

Radiotherapy-Free Pembrolizumab and Chemotherapy Challenge the Standard of Care in PD-L1 High Locally Advanced NSCLC
newsimmunotherapyNSCLC

Radiotherapy-Free Pembrolizumab and Chemotherapy Challenge the Standard of Care in PD-L1 High Locally Advanced NSCLC

By MedXY|Jan 13, 2026

The Phase 2 Evolution trial suggests that for unresectable, locally advanced NSCLC with PD-L1 TPS ≥50%, a radiotherapy-free regimen of pembrolizumab plus chemotherapy is feasible, yielding a 67% 2-year progression-free survival rate and a m

Beyond Conventional Immunotherapy: Zhenqi Fuzheng Granule Synergizes with PD-1 Blockade by Remodeling Gut-Immune Metabolism in Colorectal Cancer
Gastroenterologycolorectal cancergut microbiota

Beyond Conventional Immunotherapy: Zhenqi Fuzheng Granule Synergizes with PD-1 Blockade by Remodeling Gut-Immune Metabolism in Colorectal Cancer

By MedXY|Jan 13, 2026

Researchers have discovered that Zhenqi Fuzheng Granule enhances PD-1 antibody efficacy in colorectal cancer by modulating the gut microbiota-SCFA-GPR109A axis, effectively suppressing tumor glycolysis and reversing immune exhaustion within

Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL
newsCAR T-cell therapyDLBCL

Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL

By MedXY|Jan 13, 2026

The ZUMA-6 trial investigated combining axicabtagene ciloleucel with atezolizumab for refractory DLBCL. While the combination was safe with a 54% complete response rate, efficacy and CAR T-cell expansion were comparable to monotherapy, high

Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes
newsHNSCCimmunotherapy

Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes

By MedXY|Jan 13, 2026

A Phase II clinical trial demonstrates that combining tislelizumab with neoadjuvant chemotherapy significantly improves pathological response rates and organ preservation in patients with locally advanced head and neck squamous cell carcino

Atezolizumab Demonstrates Moderate Efficacy in TMB-High Solid Tumors: Insights from the TAPISTRY Phase II Trial
newsatezolizumabimmunotherapy

Atezolizumab Demonstrates Moderate Efficacy in TMB-High Solid Tumors: Insights from the TAPISTRY Phase II Trial

By MedXY|Jan 13, 2026

The Phase II TAPISTRY trial evaluates atezolizumab in patients with high tumor mutational burden (TMB ≥13 or ≥16 mut/Mb), showing an objective response rate of approximately 20-22% across various solid tumors with a manageable safety profil

Potent Immune Activation Fails to Translate into High Response Rates: Lessons from the Cergutuzumab Amunaleukin and Atezolizumab Phase Ib Trial
newsimmunocytokineimmunotherapy

Potent Immune Activation Fails to Translate into High Response Rates: Lessons from the Cergutuzumab Amunaleukin and Atezolizumab Phase Ib Trial

By MedXY|Jan 13, 2026

A Phase Ib study of the IL-2 variant immunocytokine cergutuzumab amunaleukin plus atezolizumab demonstrates manageable safety and robust peripheral immune activation but modest clinical activity in CEA-positive advanced solid tumors.

Limited Efficacy for Cabozantinib and Nivolumab in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from a Phase II Trial
Gastroenterologycabozantinibimmunotherapy

Limited Efficacy for Cabozantinib and Nivolumab in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from a Phase II Trial

By MedXY|Jan 13, 2026

A Phase II trial investigating the combination of cabozantinib and nivolumab in advanced extrapancreatic neuroendocrine tumors (epNETs) failed to meet its primary objective response rate endpoint, despite high rates of stable disease, highl

THAG Regimen Shows High Efficacy as Conversion Therapy for Pancreatic Cancer: New Phase II Trial Results
Gastroenterologyimmunotherapyneoadjuvant therapy

THAG Regimen Shows High Efficacy as Conversion Therapy for Pancreatic Cancer: New Phase II Trial Results

By MedXY|Jan 13, 2026

A Phase II trial demonstrates that the THAG regimen—combining immunotherapy, radiotherapy, and chemotherapy—significantly improves R0 resection rates and survival in patients with BRPC and LAPC, supported by IL-6 and ctDNA biomarker insight

Zanidatamab-Based Triplet Therapy Redefines Survival Expectations in HER2-Positive Gastric Cancer: Insights from a Phase 1b/2 Study
GastroenterologyGastric CancerHER2

Zanidatamab-Based Triplet Therapy Redefines Survival Expectations in HER2-Positive Gastric Cancer: Insights from a Phase 1b/2 Study

By MedXY|Jan 12, 2026

A phase 1b/2 trial reveals that combining the bispecific antibody zanidatamab with tislelizumab and chemotherapy yields a 75.8% response rate and an impressive median overall survival of 32.4 months in first-line HER2-positive gastric and g

Biomarkers of Benefit: tTMB and MSI Status Redefine Immunotherapy Success in Metastatic Castration-Resistant Prostate Cancer
newsbiomarkersimmunotherapy

Biomarkers of Benefit: tTMB and MSI Status Redefine Immunotherapy Success in Metastatic Castration-Resistant Prostate Cancer

By MedXY|Jan 12, 2026

A large-scale clinico-genomic study confirms that both tissue-based TMB and MSI-H independently predict significantly improved outcomes for ICI therapy in metastatic castration-resistant prostate cancer, while also validating blood-based MS

MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer
newsbiomarkersimmunotherapy

MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer

By MedXY|Jan 12, 2026

A large-scale clinico-genomic study demonstrates that both tissue-based MSI-H and TMB-H status independently predict superior outcomes for immune checkpoint inhibitors in mCRPC, while validating blood-based MSI as a viable alternative for p

Prev
4 / 9
123456…9
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure